Recent studies confirmed detection of prostate-specific membrane antigen (PSMA)-ligand in 93% of adenoid cystic carcinomas, opening perspectives for efficient therapy with 177 Lutetium PSMA [60]. This evidence concerns the gene FOLH1 and adenoid cystic carcinoma.